Jump to the top of the page

Investment Banking

The Quarterly Rx: Q2 2022 U.S. Biopharma Recap

An increase in M&A and financing activity to end biopharma's Q2 have rekindled hope that we’re finally out of the biotech winter, while others fear it’s just a false spring. As companies continue to weather the storm, the focus remains on cash runway, quality news flow/clinical data, and consolidation. William Blair's Biopharma team shares perspectives in The Quarterly Rx: Q2 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Economics Weekly: Another Possible Government Shutdown, Rising ACA Premiums, and Fiscal Cliffs Entering 2026

    In this Economics Weekly, Richard de Chazal responds to questions about another government shutdown and the enhanced Affordable Care Act (ACA) extended tax credits.

    Read more

  • Sirion Has Agreed to Receive a Majority Investment from Haveli Investments

    William Blair acted as exclusive financial advisor to Sirion, a portfolio company of Brookfield, Partners Group, Peak XV, and Tiger Global, in connection with its pending majority investment from Haveli Investments.

    Read more

  • Sur-Seal, LLC Has Been Acquired by Brodie Generational Capital Partners

    William Blair acted as the exclusive financial advisor to Sur-Seal, LLC, a portfolio company of Heartwood Partners, in connection with its sale to Brodie Generational Capital Partners.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures